Recently added

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Hasegawa, Kosei; Takahashi, Shunji ; USHIJIMA, KIMIO; Okadome, Masao; Yonemori, Kan; Yokota, Harushige; OAKNIN, ANA (Wiley, 2024-09-26)

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

Neal, Joel; Lim, Farah Louise; Fang, Bruno; Torres Lozada, Patricia; Santoro, Armando; Gonzalez-Cao, Maria; FELIP, ENRIQUETA (Elsevier, 2024-03-20)

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Navarro, Miguel; Porras, Ignacio; Hernando, Jorge; Maurente Oliveira, Eduardo; Jimenez Fonseca, Paula; Martinez-Trufero, Javier; Rubió-Casadevall, Jordi (Springer, 2024-11)

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

van de Haar, Joris; Roepman, Paul; andre, fabrice; Castro, Elena; Chakravarty, Debyani; Balmaña, Judith; Dienstmann, Rodrigo; Mateo, Joaquin (Elsevier, 2024-11)

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

Harding, James; Fan, Jia; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; OH, DO-YOUN; Macarulla, Teresa (Taylor & Francis, 2024)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer ﻿

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study ﻿

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023) ﻿

ESMO Recommendations on clinical reporting of genomic test results for solid cancers ﻿

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer ﻿

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer